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Conclusions: Proposed algorithm gives dose distribution comparable 
with those achieved by planners and therefore can serve as a support 
in creating 3D-CRT plans. It is also simple in use and can speed up the 
treatment planning process. 
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Purpose/Objective: The UMC Utrecht design of a 1.5T MR scanner 
integrated with a 6MV linear accelerator – or MRL – will have the 
ability of providing fast image-guidance with a high soft-tissue 
contrast, directly during irradiation (RT) with the patient on the MRL. 
MRI-guided treatment opens possibilities for developing new RT 
techniques. In addition, it is necessary to study the effects of the 
magnetic field itself on the dose distribution. Due to the electron 
return effect, the skin dose can be increased, depending on the 
magnetic field strength and the beam/skin inclination angle. Since 
generally large volumes of skin are included in the treatment fields in 
breast cancer patients, the objective of this treatment planning study 
is to investigate the effects on the skin dose in presence of a magnetic 
field, for whole-breast irradiation (WBI) and accelerated partial-
breast irradiation (APBI). 
Materials and Methods: In 11 patients with early-stage breast cancer, 
target volumes and organs at risk (OARs) were delineated on CT scans 
registered with MRI after breast-conserving surgery. Two intensity-
modulated radiotherapy (IMRT) techniques were considered: 
tangential WBI and seven-field APBI. Beam geometries with 
individually optimized beam angles were used for all patients. For 
WBI, dose prescription was 42.56Gy (16x2.66 Gy), while for APBI the 
prescription was 38.5Gy (10x3.85Gy). The OARs - heart, lungs, 
contralateral breast, body, skin (the first 5 mm of ipsilateral breast 
tissue) - were subject to clinical constraints. To include the magnetic 
field in the dose calculations, in-house developed treatment planning 
software was used, based on GPU-based MonteCarlo calculations, and 
Fast Inverse Dose Optimization. IMRT plans were made for magnetic 
field strengths of 0T, 0.35T, and 1.5T. All plans were generated using 
a template of cost functions. Optimization was fluence-based only. 
Results 
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WBI 0T 94.6 (0.5) 0 5.5 (2.0) 
1.7 
(2.2) 
29.9 
(1.9) 
50.6 
(6.0) 
 
0.35T 96.6 
(0.7) 0 5.6 (2.0) 
2.2 
(2.7) 
32.7 
(2.1) 
68.2 
(6.0) 
 
1.5T 96.5 
(0.7) 0 5.7 (2.0) 
2.2 
(2.7) 
34.5 
(2.2) 
73.9 
(5.2) 
APBI  0T 96.8 (0.8) 0 3.9 (1.7) 
0.7 
(1.6) 
5.2 
(2.0) 
2.5 
(2.7) 
 
0.35T 96.8 
(1.0) 0 3.6 (1.6) 
0.1 
(0.1) 
5.6 
(2.4) 
2.7 
(2.3) 
 
1.5T 96.8 
(0.7) 0 1.4 (1.4) 
0.3 
(0.8) 
5.8 
(2.4) 
3.0 
(2.3) 
For all plans the clinical dose constraints could be met using a 
template of cost functions (table 1). The skin dose was increased at 
non-zero field strengths for WBI (figure 1), while equal PTV coverage 
was achieved, with a small compromise on lung and heart dose. The 
average V35Gy for the skin was 50.6%, 68.2% and 73.9% for WBI at 0T, 
0.35T and 1.5T, respectively. For APBI, only minor effects were 
observed in the skin area: V35Gy was respectively 2.5%, 2.7% and 
3.0%.  
  
Conclusions: With the use of our planning system, acceptable IMRT 
plans for WBI and APBI in an MRL were generated employing a class 
solution. For WBI, the presence of a magnetic field resulted in an 
increased skin dose, which is a drawback if WBI treatments are to be 
performed on the MRL. For APBI however, the induced effects on the 
skin dose due to the magnetic field were small. This opens the 
possibilities for developing MR-guided treatments for APBI in the MRL. 
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Purpose/Objective: The aim of this study is to compare the dose 
distributions of intensity-modulated radiation therapy (IMRT) plans for 
patients with prostate cancer between MHI TM-2000 (VERO), 
TomoTherapy HiArt System (TomoTherapy), and conventional linac 
(Clinac 21EX), all of which are installed in our institution. 
Materials and Methods: Ten patients with localized prostate cancer 
treated by IMRT at our institution were included in this planning 
study. The clinical target volume (CTV) was defined as the prostate 
with or without the proximal seminal vesicles according to risk groups. 
The planning target volume (PTV) was defined as the CTV + three-
dimentional margins of 8 mm (5 mm on the rectal side). The rectum 
from the sigmoid flexure to the anal verge and the bladder were also 
delineated as solid organs. For each patient, IMRT planning was 
implemented for 3 different treatment machines, including VERO, 
TomoTherapy, and Clinac 21EX, so as to achieve the similar optimal 
dose delivery to the target volumes with the same dose constraints for 
normal tissues. IMRT schedule consisted of 76Gy in 38fr. As the 
method of IMRT, segmental multi-leaf collimator (MLC) IMRT with 7 
static ports, helical IMRT, and dynamic MLC IMRT with 7 static ports, 
were adopted for VERO, TomoTherapy, and Clinic 21EX, respectively. 
As planning software, iPlan ver.4.5.1, TomoTherapy Planning Station 
4.1.2, and Eclipse ver.10.0 were used for VERO, TomoTherapy, and 
Clinac 21EX, respectively.  
The dose-volume parameters described below were calculated in each 
treatment machine: D50 and D95 of the PTV and CTV; V40, V50, V60, 
V70 and V75 of the rectum; V65, V70 and V75 of the bladder. The 
mean values and standard deviations (SD) of each parameter among 
10 patients were calculated in each treatment machine, and 
compared between 3 treatment plans. 
Results: The dose-volume parameters calculated in each treatment 
machine are shown in the following Table. 
